Research Report on China’s Zoledronic Acid Market, 2016-2020 & 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Zoledronic Acid Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

Zoledronic acid was originally developed by Novartis (trade name: ZOMETA) and was initially approved for marketing in the United States in 2001 under the trade name of Zometa (4mg), mainly for the treatment of excessive calcium in the blood caused by cancer.

According to the publisher’s market research, 4mg of zoledronic acid injection was marketed by Novartis in China in 2004, while 5mg of zoledronic acid injection for osteoporosis was approved in China in 2009. Subsequently, several companies’ generic zoledronic acid drugs were marketed in China, decreasing Novartis’ share of zoledronic acid market in China.

According to the publisher’s market research, in 2020, the sales value of zoledronic acid in China declined to approximately CNY 507 million (USD78 million) because of COVID-19, with a CAGR of approximately -3.9% from 2016 to 2020. Since Novartis’ original drug sells at a much higher price than generic drugs, local Chinese company Chia Tai Tianqing Pharmaceutical then ranked the first in terms of sales value and volume in China’s zoledronic acid market in 2020.

China’s zoledronic acid market will see growth as COVID-19 is effectively controlled in China, 2021-2025.

Topics Covered:

• Impact of COVID-19 on China’s Zoledronic Acid Market
• Development Environment of Zoledronic Acid in China
• Sales Volume of Zoledronic Acid in China
• Sales Volume and Value of Zoledronic Acid in China by Region
• Major Zoledronic Acid Manufacturers in China and Their Market Shares
• Sales Price of Zoledronic Acid in China
• Prospects of China’s Zoledronic Acid Market, 2021-2025

Key Topics Covered:

1 Relevant Concepts of Zoledronic Acid

1.1 Indications of Zoledronic Acid

1.2 Development of China’s Zoledronic Acid Market

1.3 Governmental Approval of Zoledronic Acid in China

1.4 The Impact of COVID-19 on China’s Zoledronic Acid Market

2 Sales of Zoledronic Acid in China, 2016-2020

2.1 Sales Value

2.1.1 Sales Value in China

2.1.2 Sales Value in China by Region

2.2 Sales Volume

2.2.1 Sales Volume in China

2.2.2 Sales Volume in China by Region

2.3 Sales of Zoledronic Acid in China by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Other Dosage Forms

3 Analysis of Major Zoledronic Acid Manufacturers in China, 2020

3.1 Analysis of Market Share

3.1.1 Market Share of Manufacturers by Sales Value

3.1.2 Market Share of Manufacturers by Sales Volume

3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.2.1 Company Profile

3.2.2 Sales of Zoledronic Acid in China

3.3 Fresenius Kabi Austria GmbH

3.3.1 Company Profile

3.3.2 Sales of Zoledronic Acid in China

3.4 Novartis Pharma Stein AG

3.5 Sichuan Hairong Pharmaceutical Co., Ltd. of Yangzijiang Pharmaceutical Group

3.6 Jiangsu Hengrui Medicine Company Ltd.

4 Sales Price of Zoledronic Acid of Different Companies in China, 2020-2021

4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianqingyitai)

4.2 Fresenius Kabi Austria GmbH

4.3 Novartis Pharma Stein AG (ZOMETA)

4.4 Sichuan Hairong Pharmaceutical Co., Ltd. of Yangzijiang Pharmaceutical Group (Midi)

4.5 Jiangsu Hengrui Medicine Company Ltd. (Ailang)

5 Prospects of China’s Zoledronic Acid Market, 2021-2025

5.1 Influencing Factors for the Market Development

5.1.1 The Impact of COVID-19 on the Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/16agl8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900